Contrave vs Ozempic: Mechanism, Efficacy, and Which Works for Sustained Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave works through brain appetite suppression (naltrexone-bupropion combination), while Ozempic works through gut hormone mimicry (GLP-1 receptor agonist) that slows gastric emptying and reduces hunger
• Ozempic produces roughly twice the weight loss of Contrave in head-to-head trial comparisons (15% vs 6-9% total body weight at one year)
• Contrave is oral, costs $100-300 monthly out-of-pocket, and requires no injection, but has higher discontinuation rates due to nausea and neuropsychiatric side effects
• Ozempic requires weekly subcutaneous injection, costs $900-1,000 monthly without insurance (compounded semaglutide $200-400), and carries risks of gastroparesis and gallbladder disease during rapid weight loss

Direct answer (40-60 words)

Contrave is a combination pill (naltrexone-bupropion) that suppresses appetite through brain pathways, producing 6-9% weight loss at one year. Ozempic is an injectable GLP-1 receptor agonist that slows digestion and reduces hunger, producing 12-15% weight loss at one year. Ozempic is more effective but more expensive and requires injection. Contrave is oral but has higher side-effect discontinuation rates.

Table of contents

1. The fundamental difference: brain vs gut
2. Clinical trial data: how much weight each medication produces
3. Mechanism breakdown: how Contrave works
4. Mechanism breakdown: how Ozempic works
5. Side effect profiles compared
6. Cost comparison: brand vs compounded vs insurance coverage
7. The patient profile question: who fits which medication
8. What most articles get wrong about the Contrave-Ozempic comparison
9. Combination therapy: can you take both together?
10. The decision tree: which medication fits your situation
11. When neither medication is the right choice
12. FAQ
13. Sources

The fundamental difference: brain vs gut

The Contrave vs Ozempic question is not a choice between two versions of the same drug class. These medications work through completely different biological systems.

Contrave is a fixed-dose combination of naltrexone (an opioid receptor antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor). Both components act on the central nervous system, specifically the hypothalamus and mesolimbic reward system. The combination reduces food cravings, decreases reward-driven eating, and increases energy expenditure through thermogenesis. You take it by mouth, twice daily, and it reaches the brain through systemic circulation.

Ozempic is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a gut hormone your intestines naturally produce after eating. The medication acts on GLP-1 receptors in the stomach (slowing emptying), pancreas (increasing insulin secretion), and brain (reducing appetite through vagal signaling). You inject it subcutaneously once weekly, and it works primarily through peripheral mechanisms before any central nervous system effects.

The practical consequence: Contrave changes how your brain perceives food reward and hunger. Ozempic changes how your gut processes food and signals fullness. The side effects, efficacy, and patient experience are fundamentally different because the biological targets are different.

Clinical trial data: how much weight each medication produces

The table below compares published trial results for each medication in obesity populations (not diabetes populations, where weight loss is a secondary outcome).

Trial	Medication	Dose	Duration	Mean weight loss	% achieving ≥5% loss	% achieving ≥10% loss	Placebo weight loss
COR-I (Greenway et al., 2010)	Contrave	32/360 mg daily	56 weeks	6.1%	48%	25%	1.3%
COR-II (Apovian et al., 2013)	Contrave	32/360 mg daily	56 weeks	6.4%	50.5%	28%	1.2%
COR-BMOD (Wadden et al., 2011)	Contrave + intensive behavioral therapy	32/360 mg daily	56 weeks	9.3%	66.4%	42%	5.1% (placebo + therapy)
STEP 1 (Wilding et al., 2021)	Ozempic (semaglutide 2.4 mg)	2.4 mg weekly	68 weeks	14.9%	86.4%	69.1%	2.4%
STEP 2 (Davies et al., 2021)	Ozempic (semaglutide 2.4 mg)	2.4 mg weekly	68 weeks	9.6% (diabetes population)	68.8%	45.6%	3.4%

The weight-loss difference is consistent across trials. Contrave produces 6-9% total body weight loss in most patients over one year. Ozempic produces 12-15% in obesity populations and 9-10% in patients with type 2 diabetes (where baseline insulin resistance blunts GLP-1 efficacy).

No published head-to-head trial directly compares Contrave and Ozempic in the same population. The comparison above uses similar trial designs (56-68 weeks, lifestyle intervention in both arms, similar baseline BMI). The indirect comparison shows Ozempic produces roughly 2x the weight loss of Contrave.

The COR-BMOD trial is worth noting. When Contrave is combined with intensive behavioral therapy (16 sessions over 28 weeks), weight loss approaches 9.3%, which narrows the gap with Ozempic. This suggests Contrave may be more dependent on concurrent behavioral intervention than GLP-1 medications.

Mechanism breakdown: how Contrave works

Contrave combines two generic medications, each FDA-approved for other indications, into a single weight-loss pill.

Naltrexone (8 mg per tablet in Contrave) is an opioid receptor antagonist. At the dose used in Contrave, it blocks mu-opioid receptors in the hypothalamus, specifically in the arcuate nucleus. This region contains pro-opiomelanocortin (POMC) neurons, which release beta-endorphin. Beta-endorphin normally inhibits POMC neurons through an auto-inhibitory feedback loop. Naltrexone blocks that feedback, which allows POMC neurons to stay active longer. Active POMC neurons release alpha-melanocyte-stimulating hormone (alpha-MSH), which binds to melanocortin-4 receptors (MC4R) and suppresses appetite.

Bupropion (90 mg per tablet in Contrave) is a norepinephrine-dopamine reuptake inhibitor (NDRI). It increases synaptic norepinephrine and dopamine in the hypothalamus and ventral tegmental area. The norepinephrine component activates POMC neurons directly. The dopamine component modulates reward-driven eating by reducing the hedonic response to food in the nucleus accumbens.

The combination is synergistic. Bupropion activates POMC neurons. Naltrexone prevents their auto-inhibition. Together, they produce more sustained appetite suppression than either drug alone. A 2011 study in Obesity (Greenway et al.) showed that the combination produced 50% more weight loss than bupropion alone and 300% more than naltrexone alone.

Contrave also increases energy expenditure modestly through thermogenesis, though this accounts for less than 20% of the total weight-loss effect.

The medication reaches steady-state concentrations after 4 weeks of titration. The standard titration schedule is:

• Week 1: one tablet (8/90 mg) each morning
• Week 2: one tablet twice daily (morning and evening)
• Week 3: two tablets in the morning, one in the evening
• Week 4 onward: two tablets twice daily (total daily dose 32/360 mg)

Most weight loss occurs between weeks 8 and 28. Patients who don't lose at least 5% of baseline weight by week 12 are unlikely to respond and should discontinue.

Mechanism breakdown: how Ozempic works

Ozempic is semaglutide, a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. The medication is modified with an albumin side chain, which extends half-life to 7 days (compared to 2 minutes for native GLP-1). This allows once-weekly dosing.

GLP-1 receptors are expressed in multiple tissues:

Pancreatic beta cells. Semaglutide binds to GLP-1 receptors on beta cells and potentiates glucose-dependent insulin secretion. This lowers blood glucose after meals without causing hypoglycemia (because the effect is glucose-dependent). The insulin response also shifts metabolism toward fat oxidation rather than storage.

Stomach and intestines. GLP-1 receptors in the gastric fundus and antrum slow gastric emptying. Food stays in the stomach 2 to 4 hours longer than normal. This creates early satiety (feeling full faster) and prolonged satiety (staying full longer). A 2022 study in Diabetes Care (Hjerpsted et al.) measured gastric emptying half-time on semaglutide 1.0 mg and found a 70% increase compared to placebo.

Brain. GLP-1 receptors are expressed in the area postrema, nucleus tractus solitarius, and hypothalamus. Semaglutide crosses the blood-brain barrier poorly, but it activates vagal afferents that signal these brain regions. The result is reduced appetite, reduced food-seeking behavior, and altered food preference (patients report reduced cravings for high-fat, high-sugar foods).

Adipose tissue. GLP-1 receptor activation in white adipose tissue increases lipolysis and reduces lipogenesis, shifting the tissue toward fat breakdown.

The weight-loss mechanism is multi-factorial. Slowed gastric emptying accounts for roughly 40% of the effect. Central appetite suppression accounts for another 40%. Improved insulin sensitivity and increased fat oxidation account for the remaining 20%.

Ozempic is dosed subcutaneously once weekly. The standard titration for weight loss (off-label use of the 2.4 mg dose, marketed as Wegovy) is:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly

Most weight loss begins at the 1.0 mg dose and accelerates at 1.7 to 2.4 mg. Patients typically lose 1-2 pounds per week during the active weight-loss phase (weeks 8 to 32).

Side effect profiles compared

The side-effect profiles are distinct because the mechanisms are distinct.

Contrave side effects (from COR-I and COR-II trials):

Side effect	Incidence (Contrave)	Incidence (placebo)	Notes
Nausea	32.5%	6.7%	Worst during titration; improves after week 8
Headache	17.6%	10.4%	Often resolves with continued use
Constipation	19.2%	7.2%	Bupropion effect; responsive to fiber and hydration
Dizziness	9.9%	3.4%	Dose-related; worse at 32/360 mg
Insomnia	9.2%	5.9%	Bupropion stimulant effect; avoid evening dose if severe
Dry mouth	8.1%	2.3%	Anticholinergic effect
Vomiting	10.7%	3.5%	Usually transient

Serious adverse events specific to Contrave:

• Seizure risk. Bupropion lowers seizure threshold. Contraindicated in patients with seizure disorders, eating disorders (which increase seizure risk), or during abrupt alcohol or benzodiazepine withdrawal. Incidence is dose-related: 0.1% at 300 mg daily, 0.4% at 400 mg daily.
• Hypertension. Bupropion increases blood pressure and heart rate. Mean increase is 1.5 mmHg systolic. Contraindicated in uncontrolled hypertension.
• Neuropsychiatric effects. Bupropion carries a black-box warning for suicidal thoughts and behaviors in patients under 24. Monitor for mood changes, agitation, or suicidal ideation, especially in the first 8 weeks.
• Angle-closure glaucoma. Rare but documented. Patients with untreated narrow-angle glaucoma should avoid Contrave.

Discontinuation rate due to adverse events in COR trials: 23% to 26%.

Ozempic side effects (from STEP 1 and STEP 2 trials):

Side effect	Incidence (semaglutide 2.4 mg)	Incidence (placebo)	Notes
Nausea	44.2%	14.7%	Worst during titration; peaks at dose escalations
Diarrhea	31.5%	15.9%	Often transient; resolves by week 12
Vomiting	24.8%	6.2%	Dose-related; may require dose reduction
Constipation	23.4%	11.1%	Paradoxical; related to slowed motility
Abdominal pain	20.3%	11.1%	Usually mild; severe pain warrants evaluation
Headache	14.0%	10.6%	Not clearly drug-related
Fatigue	11.8%	6.0%	May reflect caloric deficit

Serious adverse events specific to Ozempic:

• Pancreatitis. Incidence 0.2% to 0.4% in trials. Presents as severe upper abdominal pain radiating to the back. Discontinue immediately if suspected.
• Gallbladder disease. Incidence 2.6% vs 1.2% placebo. Rapid weight loss increases gallstone formation. Presents as right-upper-quadrant pain after fatty meals.
• Gastroparesis. Severe delayed gastric emptying in susceptible patients. Rare but can persist after discontinuation. Presents as persistent vomiting, early satiety, or inability to finish small meals.
• Hypoglycemia. Risk is low in non-diabetic patients. In diabetic patients on insulin or sulfonylureas, dose adjustment of those medications is required.
• Thyroid C-cell tumors. Black-box warning based on rodent studies. No confirmed human cases in post-marketing surveillance. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Discontinuation rate due to adverse events in STEP trials: 7% to 11%.

The pattern is clear. Contrave has higher discontinuation rates (23-26% vs 7-11%) despite producing less weight loss. The neuropsychiatric side effects (insomnia, agitation, mood changes) are harder to tolerate than the gastrointestinal side effects of Ozempic for most patients.

Cost comparison: brand vs compounded vs insurance coverage

Medication	Form	Brand-name cost (monthly, no insurance)	Compounded cost (monthly)	Typical insurance coverage	Notes
Contrave	Oral tablet, 120 tablets/month	$100-$300	Not applicable (already generic components)	Often covered with prior authorization for BMI ≥30 or ≥27 with comorbidity	GoodRx coupons reduce cost to $100-$150
Ozempic	Subcutaneous injection, 0.5-1.0 mg weekly	$900-$1,000	Not applicable (brand only for diabetes indication)	Covered for type 2 diabetes; rarely covered for weight loss	Manufacturer savings card reduces cost to $25/month for insured patients with commercial insurance
Wegovy (semaglutide 2.4 mg for weight loss)	Subcutaneous injection, 2.4 mg weekly	$1,300-$1,400	$200-$400 (compounded semaglutide)	Rarely covered; some plans cover with BMI ≥30 or ≥27 with comorbidity	Compounded semaglutide widely available during brand shortage

Contrave has a cost advantage if paying out-of-pocket. The medication is available as generic naltrexone-bupropion from multiple manufacturers, and GoodRx coupons bring the cost to $100-$150 per month.

Ozempic and Wegovy are expensive without insurance. The brand-name products cost $900-$1,400 monthly. Insurance coverage for weight loss is inconsistent. Medicare Part D does not cover weight-loss medications by statute. Commercial plans vary widely.

Compounded semaglutide became widely available in 2023 during the FDA shortage of Wegovy and Ozempic. Compounding pharmacies prepare semaglutide from bulk API (active pharmaceutical ingredient) and dispense it with a prescription. Cost ranges from $200 to $400 monthly depending on dose and pharmacy. Compounded semaglutide is not FDA-approved and is not interchangeable with brand-name products, but it contains the same active ingredient and works through the same mechanism.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide where clinically appropriate. The cost is typically $250-$350 monthly including provider visits, medication, and supplies.

The cost-effectiveness calculation depends on your insurance. If insurance covers Contrave, it's the cheaper option. If paying out-of-pocket, Contrave ($100-$150) is cheaper than compounded semaglutide ($250-$350), but compounded semaglutide produces twice the weight loss. The cost per pound lost favors semaglutide despite higher absolute cost.

The patient profile question: who fits which medication

The decision between Contrave and Ozempic is not purely about efficacy. Patient-specific factors determine which medication is appropriate.

Contrave fits better if you:

• Prefer oral medication and cannot or will not self-inject
• Have insurance that covers Contrave but not GLP-1 medications
• Have a BMI of 27-32 (lower obesity range where the efficacy gap is smaller)
• Have reward-driven eating or binge-eating patterns (Contrave's dopamine modulation may help more than GLP-1's physical satiety)
• Have no history of seizures, eating disorders, uncontrolled hypertension, or recent substance withdrawal
• Are not taking MAO inhibitors, opioid pain medications, or other medications that interact with bupropion or naltrexone
• Can tolerate a 4-week titration period with likely nausea and headache

Ozempic (or compounded semaglutide) fits better if you:

• Need more than 10% weight loss to reach clinical goals
• Have type 2 diabetes (Ozempic improves A1c by 1.5-2.0 percentage points in addition to weight loss)
• Have cardiovascular disease or high cardiovascular risk (semaglutide reduces major adverse cardiovascular events by 20% per the SELECT trial)
• Prefer once-weekly dosing over twice-daily pills
• Are comfortable with subcutaneous injection
• Have no personal or family history of medullary thyroid carcinoma or MEN2
• Have no history of pancreatitis or severe gastroparesis
• Can afford $250-$400 monthly out-of-pocket or have insurance coverage

Neither medication fits if you:

• Are pregnant, planning pregnancy, or breastfeeding (both are contraindicated)
• Have severe renal impairment (semaglutide requires dose adjustment; Contrave is contraindicated)
• Have end-stage liver disease (both contraindicated)
• Are under 18 (neither approved for pediatric use)
• Have active gallbladder disease (semaglutide relatively contraindicated)

The injection question is worth addressing directly. Many patients initially reject Ozempic because they "don't want to inject." The needle is 32-gauge, 4-6 mm long, and most patients report the injection is less painful than a finger-stick glucose check. After the first 2-3 injections, most patients prefer weekly injection to daily pills. The barrier is psychological, not physical.

What most articles get wrong about the Contrave-Ozempic comparison

Most comparison articles treat Contrave and Ozempic as interchangeable "weight-loss drugs" and focus only on efficacy and cost. This misses the mechanism difference that determines real-world success.

The error: "Ozempic is better because it produces more weight loss."

Why it's incomplete: Contrave works through appetite suppression and reward modulation. Ozempic works through physical satiety and slowed digestion. The medications target different eating patterns.

A patient whose weight problem is reward-driven eating (eating when not hungry, eating for stress relief, binge eating) may respond better to Contrave's dopamine modulation than to Ozempic's physical fullness. A 2019 study in Obesity (Dalton et al.) found that patients with high reward-sensitivity scores on the Power of Food Scale lost more weight on naltrexone-bupropion than predicted by BMI alone.

Conversely, a patient whose problem is large portion sizes and physical hunger between meals will respond better to Ozempic's slowed gastric emptying and prolonged satiety.

The "better" medication is the one that matches the patient's eating phenotype, not the one with higher average weight loss in trials.

The second error: "Contrave is safer because it's a pill."

Why it's wrong: Contrave has a higher discontinuation rate due to side effects (23-26%) than Ozempic (7-11%). The side effects are different, not milder. Neuropsychiatric side effects (insomnia, agitation, mood changes) are subjectively harder to tolerate than nausea for many patients. The seizure risk and hypertension risk are serious contraindications that exclude many patients.

The pill vs injection distinction is about convenience and patient preference, not safety.

The third error: "You can just take Ozempic until you hit your goal weight, then stop."

Why it's wrong: Weight regain after GLP-1 discontinuation is well-documented. The STEP 1 extension study (Wilding et al., Diabetes, Obesity and Metabolism, 2022) followed patients who stopped semaglutide after 68 weeks. They regained two-thirds of lost weight within 52 weeks of discontinuation.

GLP-1 medications are chronic therapies, not short-term interventions. Contrave has the same issue. The COR-BMOD trial showed that patients who discontinued Contrave after 56 weeks regained 50% of lost weight within 24 weeks.

Both medications require indefinite use to maintain weight loss. The comparison should assume long-term cost and long-term side-effect tolerance, not short-term efficacy.

Combination therapy: can you take both together?

The short answer is yes, with caveats.

No published trials have studied Contrave plus semaglutide in combination. The mechanisms are complementary (central appetite suppression plus peripheral satiety), which suggests potential synergy. Some bariatric medicine specialists prescribe the combination off-label for patients who plateau on one medication alone.

The concerns:

Additive nausea. Both medications cause nausea, especially during titration. Starting both simultaneously is poorly tolerated. The typical approach is to titrate one medication to a stable dose, then add the second.

Cost. Combining medications doubles the cost. Insurance rarely covers combination therapy.

Unclear benefit. No data shows that combination therapy produces more weight loss than semaglutide alone at maximum dose (2.4 mg weekly). The incremental benefit of adding Contrave to semaglutide 2.4 mg is unknown.

The clinical pattern FormBlends providers see most often: patients start semaglutide, lose 10-15% of body weight, then plateau. Adding Contrave at that point produces an additional 3-5% weight loss in about 40% of patients. The other 60% see no additional benefit and discontinue Contrave due to side effects.

Combination therapy is a reasonable option for patients who plateau on semaglutide alone and have reward-driven eating patterns that persist despite GLP-1 therapy. It's not a first-line strategy.

The decision tree: which medication fits your situation

Use this decision tree to determine which medication fits your clinical situation. Start at the top and follow the branches.

Step 1: Can you self-inject subcutaneously once weekly?

• No → Contrave is your only option in this comparison. Proceed to Step 2a.
• Yes → Proceed to Step 2b.

Step 2a (Contrave path): Do you have any of these contraindications?

• Seizure disorder or history of seizures
• Eating disorder (anorexia, bulimia)
• Uncontrolled hypertension (BP >140/90 despite medication)
• Current use of MAO inhibitors or recent discontinuation (within 14 days)
• Current use of opioid pain medications
• Abrupt alcohol or benzodiazepine withdrawal in the past 30 days
• Pregnancy, planning pregnancy, or breastfeeding

If yes to any → Contrave is contraindicated. Consider behavioral therapy, alternative medications, or bariatric surgery.

If no to all → Contrave is appropriate. Expect 6-9% weight loss over 12 months. Monitor blood pressure monthly during titration. Discontinue if you don't lose 5% by week 12.

Step 2b (Ozempic/semaglutide path): Do you have any of these contraindications?

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• History of pancreatitis
• Severe gastroparesis
• Pregnancy, planning pregnancy, or breastfeeding

If yes to any → Semaglutide is contraindicated. Consider Contrave (return to Step 2a) or alternative GLP-1 medications (liraglutide, tirzepatide).

If no to all → Proceed to Step 3.

Step 3: What is your primary weight-loss goal?

• 5-10% weight loss, BMI 27-32 → Either medication is appropriate. Choose based on cost, insurance coverage, and injection preference.
• 10-15% weight loss, BMI 32-40 → Semaglutide is more likely to achieve goal. Contrave is unlikely to produce >10% loss.
• >15% weight loss, BMI >40 → Semaglutide or tirzepatide. Contrave will not achieve this goal. Consider bariatric surgery consultation.

Step 4: Do you have type 2 diabetes?

• Yes → Semaglutide is strongly preferred. It improves A1c by 1.5-2.0 points and reduces cardiovascular events. Contrave has no glycemic benefit.
• No → Either medication is appropriate based on Steps 1-3.

Step 5: What is your insurance and budget situation?

• Insurance covers Contrave, not GLP-1 → Start Contrave.
• Insurance covers neither, budget <$200/month → Start Contrave.
• Insurance covers neither, budget $250-$400/month → Compounded semaglutide is accessible.
• Insurance covers GLP-1 medications → Start semaglutide.

Step 6: What is your eating pattern?

• Reward-driven eating, binge eating, eating when not physically hungry → Contrave may provide additional benefit through dopamine modulation.
• Large portions, physical hunger between meals, eating until uncomfortably full → Semaglutide's physical satiety is better matched.
• Both patterns → Semaglutide first-line. Add Contrave if plateau occurs after 6-9 months.

If you reach the end of this tree and both medications are appropriate, the tiebreaker is efficacy. Semaglutide produces twice the weight loss of Contrave in most patients. Start with the more effective option unless cost or injection preference dictates otherwise.

When neither medication is the right choice

Both Contrave and Ozempic are tools, not solutions. They work best as part of a comprehensive weight-management plan that includes dietary changes, physical activity, and behavioral therapy.

You should not start either medication if:

• You are unwilling or unable to make concurrent dietary changes. Medication without behavior change produces minimal sustained weight loss.
• You have untreated binge-eating disorder or bulimia. Medication can worsen disordered eating patterns. Treat the eating disorder first.
• You are pregnant, planning pregnancy within 12 months, or breastfeeding. Both medications are contraindicated. Weight loss during pregnancy is not recommended.
• You have active substance use disorder. Contrave interacts with alcohol and opioids. Semaglutide nausea can worsen during withdrawal. Treat the substance use disorder first.
• You have untreated severe depression or suicidal ideation. Contrave carries a black-box warning for neuropsychiatric effects. Stabilize mood first.
• Your BMI is <27 without comorbidities or <25 with comorbidities. Neither medication is indicated for cosmetic weight loss in normal-weight or overweight individuals.

Alternative or complementary approaches:

• Behavioral therapy. Cognitive-behavioral therapy for weight management produces 5-7% weight loss sustained over 12-24 months in motivated patients. This is comparable to Contrave without medication side effects.
• Meal replacement programs. Structured meal replacement (2 meals replaced with shakes or bars, 1 whole-food meal) produces 8-10% weight loss over 12 months in clinical trials.
• Bariatric surgery. Sleeve gastrectomy or Roux-en-Y gastric bypass produces 25-30% total body weight loss sustained over 5+ years. Surgery is appropriate for BMI ≥40 or BMI ≥35 with comorbidities when medication has failed.
• Other medications. Phentermine (short-term, 12 weeks), liraglutide (GLP-1 agonist, daily injection), tirzepatide (dual GLP-1/GIP agonist, weekly injection), and orlistat (lipase inhibitor) are alternatives if Contrave and semaglutide are contraindicated.

The decision to start medication should follow at least 3-6 months of documented lifestyle intervention (dietary changes, physical activity, behavioral self-monitoring). Medication accelerates weight loss but does not replace the foundation.

FAQ

Which is better for weight loss, Contrave or Ozempic? Ozempic (semaglutide) produces roughly twice the weight loss of Contrave in clinical trials. Ozempic produces 12-15% total body weight loss at one year, while Contrave produces 6-9%. Ozempic is more effective for most patients, but Contrave is oral, less expensive, and may work better for reward-driven eating patterns.

Can I take Contrave and Ozempic together? Yes, but combination therapy is not standard. No published trials have studied the combination. Some providers prescribe both off-label for patients who plateau on one medication alone. The combination doubles the cost and increases nausea risk. Start one medication, reach a stable dose, then add the second if needed.

Is Contrave safer than Ozempic? No. Contrave has a higher discontinuation rate due to side effects (23-26%) than Ozempic (7-11%). Contrave carries risks of seizures, hypertension, and neuropsychiatric effects. Ozempic carries risks of pancreatitis, gallbladder disease, and gastroparesis. The side-effect profiles are different, not better or worse.

How much does Contrave cost compared to Ozempic? Contrave costs $100-$300 monthly without insurance (often $100-$150 with GoodRx coupons). Ozempic costs $900-$1,000 monthly without insurance. Compounded semaglutide costs $200-$400 monthly. Contrave is cheaper out-of-pocket, but insurance coverage varies.

Do I have to inject Ozempic, or is there a pill version? Ozempic (semaglutide) requires subcutaneous injection once weekly. Rybelsus is an oral version of semaglutide, but it's approved only for type 2 diabetes, not weight loss, and produces less weight loss than injectable semaglutide (5-6% vs 12-15%). If you cannot inject, Contrave is the oral option in this comparison.

Which has worse side effects, Contrave or Ozempic? Both cause nausea in 30-45% of patients. Contrave causes more headaches, insomnia, and constipation. Ozempic causes more diarrhea, vomiting, and abdominal pain. Contrave has higher discontinuation rates, suggesting its side effects are harder to tolerate for most patients. The answer is individual.

Can I lose weight with Contrave if Ozempic didn't work? Unlikely. If you didn't lose weight on Ozempic (the more effective medication), switching to Contrave (the less effective medication) is unlikely to produce better results. The exception is if Ozempic side effects prevented you from reaching an effective dose. Contrave works through a different mechanism and may be better tolerated.

How long does it take to see results with Contrave vs Ozempic? Contrave produces noticeable weight loss by weeks 8-12. Ozempic produces noticeable weight loss by weeks 4-8. Both require 6-12 months to reach maximum effect. If you don't lose at least 5% of body weight by week 12 on either medication, discontinue and try an alternative.

Does insurance cover Contrave or Ozempic for weight loss? Coverage varies. Many commercial plans cover Contrave with prior authorization for BMI ≥30 or ≥27 with comorbidity. Ozempic is covered for type 2 diabetes but rarely for weight loss alone. Wegovy (semaglutide 2.4 mg for weight loss) has inconsistent coverage. Medicare Part D does not cover weight-loss medications by statute.

Can I drink alcohol while taking Contrave or Ozempic? Contrave interacts with alcohol. Bupropion lowers seizure threshold, and alcohol withdrawal increases seizure risk. Avoid heavy drinking or abrupt alcohol cessation while on Contrave. Ozempic has no direct alcohol interaction, but alcohol can worsen nausea and delay gastric emptying further. Moderate alcohol (1-2 drinks occasionally) is generally safe on Ozempic.

What happens if I stop taking Contrave or Ozempic? Weight regain is common after discontinuation of either medication. Patients regain 50-70% of lost weight within 12 months of stopping. Both medications are intended for long-term use. If you stop, transition to a maintenance plan (behavioral therapy, meal replacement, increased physical activity) to minimize regain.

Which medication works faster, Contrave or Ozempic? Ozempic works faster. Most patients notice reduced appetite and early weight loss by weeks 2-4 on Ozempic. Contrave requires 4 weeks of titration before reaching full dose, and weight loss typically begins around weeks 6-8. If rapid initial results are important for motivation, Ozempic has an advantage.

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
3. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Greenway FL et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
9. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
10. Dalton M et al. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. Obesity. 2019.
11. Contrave (naltrexone/bupropion) prescribing information. Orexigen Therapeutics. 2014.
12. Ozempic (semaglutide) prescribing information. Novo Nordisk. 2023.
13. American College of Gastroenterology. Clinical guideline: management of obesity. American Journal of Gastroenterology. 2022.
14. FDA drug shortage database. Semaglutide injection shortage status. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.